CD8A and breast cancer: Importantly, both transgenic murine and human breast cancer studies performed in the context of HLA-A2 antigen presentation have shown that there is an expansion of MamA2.1 specific cytotoxic CD8+T-cells, thus suggesting that MamA2.1 is the immunodominant epitope to stimulate effector CD8+T cell responses [10,11].